1. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia 
Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 4, Pages e157-e166 (April 2018)
DOI: /j.clml
Copyright © 2018 Millennium: The Takeda Oncology Company Terms and Conditions

2. Figure 1
PRISMA Diagram of Study Attrition. *Includes Publications From National Guidelines Clearinghouse and National Comprehensive Cancer Network, and Proceedings From the Past 2 Meetings of the American Society of Clinical Oncology; American Society of Hematology; European Hematology Association; European Society for Medical Oncology; International Society for Pharmacoeconomics and Outcomes Research; and the International Symposium on Myelodysplastic Syndromes. **Among the 38 Publications Included, 21 Were Full-Text Articles and 17 Were Abstracts
Abbreviations: CMML = chronic myelomonocytic leukemia; HR-MDS = higher-risk myelodysplastic syndrome; MDS = myelodysplastic syndrome; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Clinical Lymphoma, Myeloma and Leukemia  , e157-e166DOI: ( /j.clml )
Copyright © 2018 Millennium: The Takeda Oncology Company Terms and Conditions